A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data
Condition(s) studied
Investigational drug(s) / intervention(s)
No Interventions: No Interventions
Study summary
The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.
Eligibility
Primary outcome measure(s)
- Brain Disease Diagnostic performance — Perioperative
This study will evaluate how accurately the AI model can identify and differentiate between: 1. Brain tumors including gliomas, glioneuronal tumors, and neuronal tumor, meningioma, germ cell tumors, embryonal tumors, tumors of the sellar region, pineal region tumors, mesenchymal, non-meningothelial tumors, choroid plexus tumors, hematolymphoid tumors, cranial and paraspinal nerve tumors, melanocytic tumors and brain metastases based on WHO CNS 5 classification; 2. Brain diseases apart from brain tumors such as brain arterial disease, neurodegenerative disorders, etc.; 3. Normal brain findings; The model's performance will be assessed using sensitivity, specificity, F1-score AUC-ROC. Diagnostic ability of AI model will be compared against with pathological diagnosis(if possible), final clinical diagnoses by neurologists or radiologists.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Xiangya Hospital of Central South University | Changsha | Hunan | Recruiting |
More Xiangya Hospital of Central South University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07126821 on ClinicalTrials.gov ↗ ← All trials in China